Brexucabtagene autoleucel (KTE-X19)

brexucabtagene autoleucel · Kite Pharma (a Gilead Company)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Brexucabtagene autoleucel (KTE-X19), covering 2021-11-29 to 2021-11-29. Get the full timeline:

Most recent: Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3) [Phase 1, Phase 2]

See pricing